In the United States, >2 million people are projected to be diagnosed with cancer in 2025, and ~20% of these patients will have a diabetes diagnosis (1–3). Hyperglycemia and cancer have a bidirectional relationship, and managing blood glucose in patients with cancer is complex because hyperglycemia may result from the underlying cancer or from anticancer or supportive care therapies that are administered intermittently (2). Hyperglycemia can worsen survival and increase risks of cancer recurrence, infection, hospitalization, toxicity, and morbidity (2). Allogeneic hematopoietic cell transplant (HCT) recipients are especially vulnerable because of insulin resistance and the use of immunosuppressants such as calcineurin inhibitors and corticosteroids for the prophylaxis and treatment of graft-versus-host disease (GVHD) (4,5). Additionally, 20–60% of patients with cancer experience treatment-induced hyperglycemia from agents such as immune checkpoint inhibitors, mammalian target of rapamycin inhibitors, phosphoinositide 3‐kinase inhibitors, and epidermal growth factor inhibitors (2).
Mnatzaganian et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: